Periodically updating coronavirus disease 19(COVID-19)vaccines that offer broad-spectrum protection is needed giventhe strong immune evasion by the circulating omicron sublineages.The effectiveness of prototype and BA...Periodically updating coronavirus disease 19(COVID-19)vaccines that offer broad-spectrum protection is needed giventhe strong immune evasion by the circulating omicron sublineages.The effectiveness of prototype and BA.4/5-containing bivalent mRNA vaccines is reduced when XBB subvariants predominate.We initiated an observer-blinded,threearms study in 376 patients in Chinese individuals aged from 18 to 55 years old who had previously received three dosesCOVID-19 vaccine.Immunogenicity in terms of neutralizing antibodies elicited by a 30-mg dose of XBB.1.5-containingbivalent vaccine(RQ3027),a 30-mg dose of BA.2/BA.5-Alpha/Beta bivalent vaccine(RQ3025)and their precedent 30-mg Alpha/Beta(combined mutations)monovalent mRNA vaccine(RQ3013)and safety are primary and secondary endpoints,respectively.We recorded prescribed COVID-19 cases to explore the preliminary efficacy of three vaccines.RQ3027 and RQ3025 boosters elicited superior neutralizing antibodies(NAbs)against XBB.1.5,XBB.1.16,XBB.1.9.1,and JN.1 compared to RQ3013 at day 14 in participants without SARS-CoV-2 infection.All study vaccines were welltolerated without serious adverse reactions identified.The incidence rates per 1000 person-years of COVID-19 casesduring the 2nd-19th week after randomization were lowest in RQ3027.Overall,our data show that XBB.1.5-containingbivalent booster generated superior immunogenicity and better protection against newer severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)variants compared to BA.2/BA.5-containing bivalent and Alpha/Beta monovalentwith no new safety concerns.展开更多
奥密克戎变异株XBB.1.16于2023年1月9日在印度首次被发现,其病毒表面刺突(Spike,S)蛋白的E180V、T478R、F486P突变增加了病毒的传播力、致病性和免疫逃逸能力,使得在美国、印度等国家的新冠病例数激增。2023年4月17日,世界卫生组织指定X...奥密克戎变异株XBB.1.16于2023年1月9日在印度首次被发现,其病毒表面刺突(Spike,S)蛋白的E180V、T478R、F486P突变增加了病毒的传播力、致病性和免疫逃逸能力,使得在美国、印度等国家的新冠病例数激增。2023年4月17日,世界卫生组织指定XBB.1.16为感兴趣的变异株(variant of interest,VOI),但未观察到疾病严重程度的增加或额外的公共健康风险,其全球评估风险较低。本文通过文献阅读和数据库检索分析,对XBB.1.16流行情况和病原学特征进行总结,为新冠病毒防控策略的制定及疫苗、药物的研究提供科学参考。展开更多
基金supported by a grant(2023YFC2307600,to Z.J.Z.)from the Na-tional Key Research and Development Program of Chinaa grant(202102AA100051,to Z.J.Z.)from the Yunnan Provincial Sci-ence and Technology Department,China+2 种基金a grant(H-2018102,to J.W.)from the High-level Health Technical Personnel Project of Yunnan Province,Chinaa grant(2022SCP001,to Z.J.Z.)from the Spring City Plan:The High-level Talent Promotion and Training Project of Kunmingand a grant(32371000,to C.M.L.)from the National Natural Science Foundation of China.
文摘Periodically updating coronavirus disease 19(COVID-19)vaccines that offer broad-spectrum protection is needed giventhe strong immune evasion by the circulating omicron sublineages.The effectiveness of prototype and BA.4/5-containing bivalent mRNA vaccines is reduced when XBB subvariants predominate.We initiated an observer-blinded,threearms study in 376 patients in Chinese individuals aged from 18 to 55 years old who had previously received three dosesCOVID-19 vaccine.Immunogenicity in terms of neutralizing antibodies elicited by a 30-mg dose of XBB.1.5-containingbivalent vaccine(RQ3027),a 30-mg dose of BA.2/BA.5-Alpha/Beta bivalent vaccine(RQ3025)and their precedent 30-mg Alpha/Beta(combined mutations)monovalent mRNA vaccine(RQ3013)and safety are primary and secondary endpoints,respectively.We recorded prescribed COVID-19 cases to explore the preliminary efficacy of three vaccines.RQ3027 and RQ3025 boosters elicited superior neutralizing antibodies(NAbs)against XBB.1.5,XBB.1.16,XBB.1.9.1,and JN.1 compared to RQ3013 at day 14 in participants without SARS-CoV-2 infection.All study vaccines were welltolerated without serious adverse reactions identified.The incidence rates per 1000 person-years of COVID-19 casesduring the 2nd-19th week after randomization were lowest in RQ3027.Overall,our data show that XBB.1.5-containingbivalent booster generated superior immunogenicity and better protection against newer severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)variants compared to BA.2/BA.5-containing bivalent and Alpha/Beta monovalentwith no new safety concerns.
文摘奥密克戎变异株XBB.1.16于2023年1月9日在印度首次被发现,其病毒表面刺突(Spike,S)蛋白的E180V、T478R、F486P突变增加了病毒的传播力、致病性和免疫逃逸能力,使得在美国、印度等国家的新冠病例数激增。2023年4月17日,世界卫生组织指定XBB.1.16为感兴趣的变异株(variant of interest,VOI),但未观察到疾病严重程度的增加或额外的公共健康风险,其全球评估风险较低。本文通过文献阅读和数据库检索分析,对XBB.1.16流行情况和病原学特征进行总结,为新冠病毒防控策略的制定及疫苗、药物的研究提供科学参考。
